Aihua Wang
Capital Medical University
Internal medicineRandomized controlled trialPlaceboPulmonary embolismType 2 diabetesDyslipidemiaVenous thrombosisType 2 Diabetes MellitusSodium/Glucose Cotransporter 2Blood viscosityDiabetes mellitusMedicineRelative riskGastroenterologyMeta-analysis
2Publications
2H-index
3Citations
Publications 3
Newest
#1Aihua Wang (Capital Medical University)H-Index: 2
#2Huilin Tang (UF: University of Florida)H-Index: 22
Last. Xin Feng (Capital Medical University)H-Index: 1
view all 4 authors...
Abstract null null Aims null This network meta-analysis aimed to evaluate the asthma risk associated with dipeptidyl peptidase (DPP)-4 inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1RAs), and sodium-glucose co-transporter (SGLT) 2 inhibitors. null null null Methods null Electronic databases were systematically searched up to March 2021 to include placebo-controlled cardiovascular (or cardiorenal) outcome trials that reported the asthma incidents in patients taking DPP-4 inhibitors, ...
Source
#1Dandan Li (Capital Medical University)H-Index: 8
#2Tingxi Wu (Capital Medical University)H-Index: 1
Last. Yiqing Song (IUPUI: Indiana University – Purdue University Indianapolis)H-Index: 68
view all 7 authors...
PURPOSE: Sodium glucose cotransporter 2 (SGLT2) inhibitors are shown to cause small, but significant changes of lipid profiles, we aim to investigate whether such altered lipid profiles can be translated into clinically meaningful changes in dyslipidemia. METHODS: PubMed, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) were searched for randomized controlled trials (RCTs) that compared SGLT2 inhibitors with placebo or other oral glucose-lowering drugs in patients with type 2...
Source
#1Aihua Wang (Capital Medical University)H-Index: 2
#2Keming Yang (IUPUI: Indiana University – Purdue University Indianapolis)H-Index: 2
Last. Xin Feng (Capital Medical University)H-Index: 1
view all 6 authors...
BACKGROUND: It has been reported that sodium-glucose cotransporter 2 (SGLT2) inhibitors could increase blood viscosity, which may further increase risk of venous thromboembolism (VTE). Therefore, we conducted a meta-analysis to evaluate the association between SGLT2 inhibitors and risk of VTE in patients with type 2 diabetes. METHODS: We systematically searched electronic databases up to April 2019 to identify randomized trials that reported the events of VTE in SGLT2 inhibitors group and contro...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.